TQB2618 + penpulimab + TQB3617

This drug is a **combination therapy** consisting of TQB2618, penpulimab, and TQB3617. - **Penpulimab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor and developed primarily for nasopharyngeal carcinoma (NPC). It blocks PD-1-mediated immune evasion, enabling T cell–mediated anti-tumor effects[1][5][7]. - **TQB3617** is a small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. It disrupts the binding of BET proteins to acetylated lysine residues on histones, thereby blocking key gene transcription and chromatin regulation pathways involved in tumor proliferation[2][4][8]. - **TQB2618** is likely another investigational compound from the same developer, but detailed mechanism of action and modality data are not available in the provided sources. The combination is experimental and aims to deliver synergistic anti-tumor effects via immune checkpoint blockade (anti-PD-1) and transcriptional modulation (BET inhibition). Primary indications under investigation are **solid tumors and hematologic malignancies**, notably **nasopharyngeal carcinoma** and **myelofibrosis**.

Brand names

penpulimab-KCQX

Other names

TQB2618TQB-2618TQB 2618penpulimabAK105AK-105AK 105TQB3617TQB-3617TQB 3617